Clonality and antimicrobial susceptibility of Burkholderia cepacia complex isolates collected from cystic fibrosis patients during 1998-2013 in Bern, Switzerland

摘要

For the first time, we analyzed the clonality and susceptibility of Burkholderia cepacia complex isolates (n=55) collected during 1998-2013 from 44 Swiss cystic fibrosis (CF)-patients. B. cenocepacia (n=28) and B. multivorans (n=14) were mainly of sequence type (ST) 833 and ST874, respectively; B. contaminans isolates were of ST102. Overall, the following MIC(50/90)s (mg/l) were obtained: piperacillin/tazobactam (<= 4/>= 128), ticarcillin/clavulanate >= 256/>= 256), ceftazidime (2/>= 32), aztreonam (16/>= 32), meropenem (2/8), tobramycin (8/>= 16), minocycline (<= 1/16), levofloxacin (<= 0.5/>= 16), and trimethoprim/sulfamethoxazole (<= 0.5/4). This is the first survey providing information on the clonality of Bcc detected in Switzerland. Species identification and antimicrobial susceptibility tests should always be routinely performed to adapt more targeted therapies.